XML 123 R104.htm IDEA: XBRL DOCUMENT v3.25.1
Collaborative and Other Relationships - Samsung Bioepis (Details)
$ in Millions
1 Months Ended 3 Months Ended 12 Months Ended
Dec. 31, 2019
product
Mar. 31, 2025
USD ($)
Dec. 31, 2024
USD ($)
Mar. 31, 2024
USD ($)
Dec. 31, 2024
USD ($)
Collaborative arrangements and non-collaborative arrangement transactions          
Payments to Acquire Intangible Assets   $ 10.0   $ 75.0  
Collaboration profit sharing/(loss reimbursement)   58.1   65.6  
Samsung Bioepis          
Collaborative arrangements and non-collaborative arrangement transactions          
Collaboration profit sharing/(loss reimbursement)   $ 48.0   $ 60.6  
Samsung Bioepis          
Collaborative arrangements and non-collaborative arrangement transactions          
Contingent Commercialized Rights, Number Of Products | product 2        
Expected profit share percentage 45.00% 50.00%      
Impairment of intangible assets (excluding goodwill)         $ 20.2
Payments to Acquire Intangible Assets     $ 15.0    
Estimated additional payments upon achievement of development and commercial milestones     150.0   150.0
Collaboration agreement term   5 years      
Option exercise fee   $ 60.0      
Samsung Bioepis | Related Party          
Collaborative arrangements and non-collaborative arrangement transactions          
Accounts receivable   3.9 7.6   7.6
Accounts payable   $ 72.9 $ 60.8   $ 60.8